Gadi Lachman Steps Down as TriNetX's CEO After Over a Decade of Leadership

Gadi Lachman Steps Down from CEO Role at TriNetX

In a significant shift for the healthcare data industry, Gadi Lachman, the innovative leader behind TriNetX, has announced his resignation as the company's CEO, effective March 31, 2025. This comes after an impressive 11-year tenure during which Lachman co-founded the company and shaped it into the world's largest source of real-world data for clinical research.

TriNetX, established in 2014, has grown incredibly under Lachman's guidance, offering clinical researchers and healthcare professionals access to extensive datasets from over 25 countries. The platform allows for tens of millions of queries each month, facilitating groundbreaking research and saving lives globally. Lachman expressed his gratitude, stating, "It has been an honor to build TriNetX and be part of such an outstanding team."

The leadership transition will see Jeff Margolis, a current board member, stepping in as Executive Chairman until a new CEO is appointed. This move aims to ensure stability and continuity in governance during this crucial transition phase. Margolis emphasized the board's appreciation for Lachman's contributions, stating, "On behalf of the Board, we thank Gadi for shaping and leading TriNetX into the world's top ecosystem of real-world data."

As Lachman prepares to step back from his operational role, he will continue to play an integral part in TriNetX's future as a member of its Board of Directors and as an advisor to Carlyle, the company’s majority investor. The strategic partnership has been pivotal in TriNetX's journey, allowing it to maintain profitability and innovation amidst high growth.

Throughout its history, TriNetX has focused on advancing global healthcare by utilizing real-world data to inform clinical trial designs and streamline operations, thereby enriching the generation of real-world evidence. The organization operates a self-service, HIPAA-compliant platform that safeguards patient privacy while enhancing trial efficiency.

The board and entire TriNetX team remain dedicated to Lachman’s vision, striving to drive innovation and fulfill the company's mission of improving healthcare outcomes worldwide. As they commence their search for a successor, Lachman's legacy as a pioneer in the field of real-world data is expected to resonate long after he steps down.

In the words of Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, "Thanks to Gadi's disciplined leadership, TriNetX has not just thrived but has also paved the way for new leadership to guide the company through its next exciting chapter."

TriNetX continues to attract attention as a vital resource for life sciences and healthcare entities, proving instrumental in developing new therapies efficiently. Their innovative approach combines a commitment to data integrity with a collaborative spirit, advancing both scientific discovery and patient care.

For ongoing updates and more information about TriNetX, visit their official website at TriNetX.com.